Cytos Rises After Asthma Drug Succeeds in Trial: Zurich Mover

Cytos Biotechnology AG, a Swiss developer of an experimental drug for allergic asthma, rose to the highest in almost two months after the medicine met its main goals in a patient study.

Cytos climbed 9.7 percent to 4.29 Swiss francs in Zurich, the highest since Jan. 16, giving the Schlieren, Switzerland-based company a market value of 96.2 million francs ($101 million). Almost 280,000 shares were traded, six times the three-month daily average. The stock was the second-biggest gainer on the Swiss Performance Index.

In a trial among 63 patients in Germany, those treated with the drug, CYT003, had improved control of their asthma after treatment with inhaled corticosteroids stopped, while those who received a placebo saw their disease worsen, Cytos said in a statement today. The drug was safe and generally well-tolerated, Cytos said.

Results from a follow-up trial in 360 patients that started in the fourth quarter of last year are expected in the first half of 2014, Cytos said.

Before it's here, it's on the Bloomberg Terminal.